Kerr Douglas 4

What Happened Kerr Douglas, Chief Medical Officer of Dyne Therapeutics (DYN), sold 887 shares in an open-market/private sale on June 16, 2026. The weighted average sale price was $18.33 per share for a total of approximately $16,259. The sale was an automatic disposition to satisfy tax-withholding obligations tied to the vesting of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-06-16 (reported on Form 4 filed 2026-06-17) — appears timely.
• Transaction type: Sale (S) of 887 shares; weighted average price $18.33; reported price range $18.00–$18.70 across multiple trades.
• Total proceeds: ~$16,259.
• Reason/footnote: Automatic sale to satisfy tax withholding on RSU vesting (per RSU agreement); characterized as a non-discretionary sale consistent with a Rule 10b5-1 affirmative defense (Footnote F1).
• Holdings note: Footnote F3 states 145,313 unvested RSUs are included in reported holdings.
• Filing specifics: F2 notes the reported price is a weighted average and the filer can provide per-trade price details on request.

Context This was a routine, tax-withholding sale tied to RSU vesting rather than a discretionary sale motivated by trading decisions. Such automatic withholding dispositions are common and do not necessarily signal insider sentiment about the company.